Renaissance Technologies
SPRO icon

Renaissance Technologies’s Spero Therapeutics SPRO Stock Holding History

Renaissance Technologies’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.09M Sell
947,904
-241,331
-20% -$631K ﹤0.01% 1933
2026
Q1 		$2.78M Sell
1,189,235
-90,287
-7% -$214K ﹤0.01% 1699
2025
Q4 		$2.98M Sell
1,279,522
-173,243
-12% -$402K ﹤0.01% 1630
2025
Q3 		$2.73M Buy
1,452,765
+620,600
+75% +$1.36M ﹤0.01% 1870
2025
Q2 		$2.41M Sell
832,165
-138,742
-14% -$200K ﹤0.01% 1995
2025
Q1 		$699K Sell
970,907
-134,684
-12% -$114K ﹤0.01% 2602
2024
Q4 		$1.14M Buy
1,105,591
+130,938
+13% +$156K ﹤0.01% 2426
2024
Q3 		$1.31M Sell
974,653
-1,299
-0.1% -$1.74K ﹤0.01% 2294
2024
Q2 		$1.27M Buy
975,952
+121,492
+14% +$183K ﹤0.01% 2183
2024
Q1 		$1.47M Buy
854,460
+306,995
+56% +$481K ﹤0.01% 2237
2023
Q4 		$805K Buy
547,465
+300
+0.1% +$358 ﹤0.01% 2543
2023
Q3 		$662K Sell
547,165
-46,266
-8% -$64.1K ﹤0.01% 2574
2023
Q2 		$860K Buy
593,431
+183,131
+45% +$313K ﹤0.01% 2561
2023
Q1 		$595K Buy
410,300
+67,400
+20% +$113K ﹤0.01% 2790
2022
Q4 		$593K Buy
342,900
+128,200
+60% +$239K ﹤0.01% 2853
2022
Q3 		$429K Sell
214,700
-724,317
-77% -$720K ﹤0.01% 3018
2022
Q2 		$696K Buy
939,017
+829,917
+761% +$2.41M ﹤0.01% 2949
2022
Q1 		$949K Buy
+109,100
New +$1.12M ﹤0.01% 2762
2020
Q4 		– Sell
-153,203
Closed -$1.71M – 3698
2020
Q3 		$1.71M Sell
153,203
-176,700
-54% -$2.09M ﹤0.01% 2227
2020
Q2 		$4.46M Buy
329,903
+5,600
+2% +$62.9K ﹤0.01% 1718
2020
Q1 		$2.62M Sell
324,303
-13,900
-4% -$123K ﹤0.01% 1913
2019
Q4 		$3.25M Buy
338,203
+85,400
+34% +$921K ﹤0.01% 2091
2019
Q3 		$2.68M Buy
252,803
+37,900
+18% +$399K ﹤0.01% 2121
2019
Q2 		$2.47M Buy
214,903
+101,600
+90% +$1.22M ﹤0.01% 2222
2019
Q1 		$1.45M Buy
113,303
+70,400
+164% +$747K ﹤0.01% 2490
2018
Q4 		$264K Buy
42,903
+30,903
+258% +$250K ﹤0.01% 3071
2018
Q3 		$126K Buy
+12,000
New +$139K ﹤0.01% 3219

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies's SPRO Position: Q2 2026 in Review

Renaissance Technologies reduced its Spero Therapeutics (SPRO) stake by 20% in Q2 2026, selling an estimated $631K and leaving 947,904 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

Renaissance Technologies first reported a position in SPRO in Q3 2018 and has held it in 27 quarters since. The position peaked at $4.46M in Q2 2020. 34 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Renaissance Technologies held 947,904 shares of Spero Therapeutics worth $2.09M as of Q2 2026.
  • Renaissance Technologies sold 241,331 Spero Therapeutics shares in Q2 2026, an estimated $631K.
  • Spero Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1933 holding.
  • Renaissance Technologies first reported a position in Spero Therapeutics in Q3 2018 and has held it in 27 quarters since.
  • Renaissance Technologies's Spero Therapeutics position peaked at $4.46M in Q2 2020.
  • 34 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.